<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Emergence from general anesthesia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Emergence from general anesthesia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Emergence from general anesthesia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sher-Lu Pai, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam King, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H468714933"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Emergence is a passive process with the gradual return of consciousness after discontinuing administration of anesthetic and adjuvant agents at the end of the surgical procedure. Most patients transition smoothly from a surgical anesthetic state to an awake state with intact protective reflexes.</p><p>This topic will discuss preparations and techniques for emergence from general anesthesia, as well as problems that may occur during this period. Extubation of the trachea at the end of a surgical procedure is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94224.html" rel="external">"Extubation following anesthesia"</a>.)</p><p>Induction and maintenance of general anesthesia are discussed in separate topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/94135.html" rel="external">"Induction of general anesthesia: Overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview"</a>.)</p><p></p><p class="headingAnchor" id="H4005675901"><span class="h1">PREPARATIONS FOR EMERGENCE</span><span class="headingEndMark"> — </span>Preparations for emergence are initiated as the surgical procedure is ending.</p><p class="headingAnchor" id="H4221991211"><span class="h2">Discontinue anesthetic agents</span><span class="headingEndMark"> — </span>Optimal timing for discontinuation of inhalation and/or intravenous (IV) anesthetic agents depends on the specific agents and doses employed and the duration of their administration. To prevent emergence that is either too early or delayed, timing for discontinuation must be individually planned for each inhalation and/or IV agent as the surgical procedure nears completion.</p><p class="headingAnchor" id="H142785507"><span class="h3">Inhalation agents</span><span class="headingEndMark"> — </span>Clearance of inhalation agents with termination of anesthetic effects and return to wakefulness depends on the presence of a concentration gradient favoring clearance from brain to blood, then from blood to alveoli (where the agent is exhaled from the body). Clearance by exhalation depends on the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partition coefficients of the selected inhalation agent </strong>– Speed of recovery from anesthesia is faster if the selected agent has a lower blood:gas partition coefficient (ie, the ratio of agent solubility in blood to its solubility in gas), brain:blood partition coefficient (ie, the ratio of agent solubility in brain to its solubility in blood), and tissue:blood partition coefficient (ie, the ratio of agent solubility in tissue to its solubility in blood)  (<a class="graphic graphic_table graphicRef113972" href="/z/d/graphic/113972.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. These concepts are explained in detail in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Partition coefficients and potency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minute ventilation</strong> – Minute ventilation is the volume of gas exchanged in the patient's respiratory system per unit of time. A faster clearance of inhalation agents occurs with higher minute ventilation, which depends on the patient's tidal volume (TV) and respiratory rate (RR). (See  <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Respiratory factors'</a>.)</p><p></p><p class="bulletIndent1">Near the end of surgical procedure, the RR is typically decreased, so the arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>) will increase to facilitate return of spontaneous breathing due to responses of the CNS chemoreceptors to hypercapnia and/or acidosis. However, this practice may reduce minute ventilation enough to delay removal of inhalation anesthetics; if so, emergence from general anesthesia may be delayed. For this reason, we decrease the patient's RR only after inhalation agents have been eliminated using a higher minute ventilation. Also, if the patient's end tidal carbon dioxide (ETCO<sub>2</sub>) during surgery has been appropriately maintained at approximately 40 mmHg, then only minimal reduction in RR will be needed. (See  <a class="medical medical_review" href="/z/d/html/93386.html" rel="external">"Mechanical ventilation during anesthesia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac output</strong> – Generally, increased cardiac output (CO) during emergence increases washout of inhalation agent from the brain and other tissue compartments, potentially speeding emergence. However, the effect of CO on speed of emergence is a complex interaction between tissue washout and pulmonary clearance. (See  <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Cardiovascular factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique-related factors</strong> – (See  <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Technique-related considerations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of administration</strong> – Prolonged administration of an agent with a higher tissue:blood partition coefficient and tissue solubility prolongs emergence, particularly when a more potent lipophilic agent (eg, <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">isoflurane</a>) is administered. (See  <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Oil:gas partition coefficient/potency'</a>.)</p><p></p><p class="bulletIndent2">Phenomena related to partition coefficients, as noted above (see  <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Partition coefficients and potency'</a>), are further explained by context-sensitivity decrement times for each inhalation agent, which correlate the duration of agent administration with the time needed to decrease its tissue concentration. Prolonged duration of administration increases the degree to which agent accumulates in tissue depots and slows the decrease in agent concentration during emergence.</p><p></p><p class="bulletIndent2">Also, higher agent solubility promotes a greater accumulation of agent in tissues and slows overall concentration equilibration time, with complex effects on speed of emergence [<a href="#rid2">2</a>]. For example, the time to decrease tissue concentration after discontinuing a potent volatile inhalation agent is relatively short and similar for <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">isoflurane</a>, <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">sevoflurane</a>, and <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">desflurane</a> if duration of administration was &lt;60 minutes. However, if duration of anesthetic administration is &gt;60 minutes for isoflurane or &gt;120 minutes for sevoflurane, the time required to decrease tissue concentration of these agents is much longer than that for desflurane  (<a class="graphic graphic_figure graphicRef118711" href="/z/d/graphic/118711.html" rel="external">figure 1</a>). For sevoflurane, this disadvantage can be overcome if sevoflurane is weaned during the final 15 minutes of surgery, and return of airway reflexes is as rapid as it would be after discontinuation of desflurane [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inhaled concentration of anesthetic agent</strong> – If concentration of inhaled agent is reduced to zero (ie, discontinuation of agent administration), the resultant concentration gradient favors transfer of agent from blood to alveoli, with subsequent elimination via exhalation. (See  <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Concentration effect'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fresh gas flow in the breathing circuit</strong> – High fresh gas flow prevents rebreathing of inhaled gas containing any anesthetic agent, thereby contributing to rapid washout.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Elimination of coadministered of </strong><a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a><strong> (N</strong><strong><sub>2</sub></strong><strong>O)</strong> – The low blood:gas partition coefficient of N<sub>2</sub>O allows its rapid elimination via alveoli at the end of procedure (see  <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Nitrous oxide'</a>). Bulk transfer of N<sub>2</sub>O gas out of the blood promotes accelerated reduction of the partial pressure of coadministered volatile inhaled anesthetic agents, facilitating faster emergence. This phenomenon is termed the "second gas" effect [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Second gas effect'</a>.)</p><p></p><p class="bulletIndent2">However, such bulk diffusion of N<sub>2</sub>O gas into alveoli during emergence also decreases alveolar oxygen (O<sub>2</sub>) concentration, which may cause diffusion hypoxia. This is prevented by delivery of high inspired O<sub>2</sub> concentration for several minutes before and after discontinuing N<sub>2</sub>O. (See  <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Disadvantages and adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H1838727796"><span class="h3">Intravenous agents</span><span class="headingEndMark"> — </span>For IV agents, recovery time depends on the rate of decrease of the agent from the central compartment (brain), either by redistribution or elimination. The metabolism of each agent depends on adequacy of the patient's liver and/or kidney function, potency of each agent, multi-compartmental pharmacokinetics after bolus and/or continuous infusion doses of each agent, and whether any administered agent has active metabolites.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bolus doses</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sedative-hypnotic agents </strong>– After a bolus injection, duration of action is short for most anesthetic agents. For example, the duration of action after a bolus dose of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> (eg, for induction of anesthesia) is approximately 10 minutes. Termination of action is due to rapid redistribution of this lipophilic agent from brain into a very large volume of distribution that includes other fatty tissues. Metabolism and excretion play minor roles in termination of effects following a single bolus. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Propofol'</a> and  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Sedative-hypnotic agent: Propofol'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opioids </strong>–<strong> </strong>Similarly, duration of action is short for most opioids administered via bolus injection to provide the analgesic component of a total intravenous anesthesia (TIVA) technique or as adjuvant agents during an inhalation anesthetic technique. For example, the duration of action after a <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> bolus is relatively short, approximately 30 to 45 minutes, primarily due to redistribution and its high lipid solubility, while the duration of action of the highly lipophilic opioid <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> is extremely short due to extremely rapid distribution to highly perfused tissues (eg, brain, heart, kidney, and gastrointestinal tract)  (<a class="graphic graphic_figure graphicRef109504" href="/z/d/graphic/109504.html" rel="external">figure 2</a> and <a class="graphic graphic_table graphicRef111780" href="/z/d/graphic/111780.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combinations of agents </strong>– Combinations of anesthetic, opioid, and adjuvant agents result in synergistic rather than merely additive effects, necessitating dose reductions for each agent during the maintenance phase of anesthesia [<a href="#rid6">6-8</a>]. Such combinations of agents also result in increased total recovery time due to both the direct synergistic effects that may prolong the duration of an anesthetized state, as well as indirect effects such as respiratory depression causing delay in elimination of inhalation anesthetics and/or sedation due to carbon dioxide (CO<sub>2</sub>) narcosis. Specific examples of combinations of anesthetic and analgesic agents that may delay emergence include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a><strong> </strong>– Synergy occurs when propofol, a sedative-hypnotic agent primarily acting on gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptors, is administered concomitantly with medications acting on other receptor types. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Sedative-hypnotic agent: Propofol'</a> and  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Sedative-hypnotic agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opioids</strong> – Opioids are commonly used as part of many general anesthetic techniques due to their analgesia, anxiolysis, and stress-response blunting effects. Their sedative effects are synergistic with all other anesthetic and adjuvant agents. Since opioids may contribute to delayed emergence when combined with other anesthetics, the benefits of opioid administration must be weighed against the possibility of respiratory depression, CO<sub>2</sub> narcosis, and sedation in the selection and dosing of specific opioid agents before emergence. (See  <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations"</a> and  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Opioids'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> – Dexmedetomidine, a highly selective alpha<sub>2</sub> agonist acting on receptors in the brain and spinal cord, may be administered in the perioperative period to take advantage of its analgesic, sedative, anxiolytic, and sympatholytic properties [<a href="#rid9">9,10</a>]. This adjuvant anesthetic agent has synergistic effects when combined with anesthetic and opioid agents that act on other receptors; thus, dexmedetomidine reduces intraoperative dose requirements for these other agents [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> has a variable context-sensitive half-time after continuous infusion depending on the duration of infusion (eg, four minutes after infusion for 10 minutes; 250 minutes after infusion for eight hours) [<a href="#rid13">13</a>]. Resolution occurs gradually after discontinuation of dexmedetomidine, such that residual sedation, reduced ventilatory responses to hypoxia and hypercapnia, as well as hemodynamic depression of heart rate (HR) and blood pressure (BP), may persist in the early postoperative period [<a href="#rid12">12,14,15</a>]. This leads to difficulty in decisions regarding optimal timing for discontinuation of dexmedetomidine infusion in preparation for emergence from general anesthesia. Since there are no reversal agents for alpha<sub>2</sub>-adrenergic agonists, timely discontinuation of administration or reduction of infusion rate is particularly important in planning for emergence. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Dexmedetomidine'</a> and  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Sedative-hypnotic agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a><strong> </strong>– As a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that blocks glutamate, ketamine produces dissociative anesthesia with profound analgesia. Clinical signs of ketamine overdose during and immediately after emergence include emergence delirium, delayed emergence, and respiratory depression [<a href="#rid16">16,17</a>], and even a single subanesthetic dose of ketamine can cause hallucination and nightmares [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/298.html" rel="external">"Ketamine poisoning", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Evaluation and treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">Lidocaine</a><strong> </strong>– Lidocaine is occasionally employed as an adjuvant agent during general anesthesia, typically administered as a bolus dose followed by a continuous infusion [<a href="#rid19">19</a>]. It reduces total <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> dosage during a TIVA technique, and reduces minimum alveolar concentration (MAC) for volatile agents observed during an inhalation anesthetic technique [<a href="#rid7">7,20,21</a>]. During emergence, excessive lidocaine levels may cause CNS toxicity manifesting as delayed emergence due to sedation or emergence agitation. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Lidocaine'</a> and  <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">"Major side effects of class I antiarrhythmic drugs", section on 'Neurologic toxicity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benzodiazepines</strong> – A benzodiazepine, typically <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>, may have been administered for anxiolytic effect. Sedative and respiratory depressant effects of benzodiazepines are synergistic with other anesthetic and adjuvant agents, particularly when midazolam is combined with <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> [<a href="#rid7">7</a>]. Also, there are potential adverse effects such as amnesia, drowsiness, and cognitive dysfunction [<a href="#rid22">22</a>], as well as an unpredictable and relatively high risk of paradoxical reactions such as irritability and aggressiveness during emergence [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Benzodiazepines'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other agents</strong> – Other agents with sedative effects may delay emergence if administered in the preoperative or intraoperative period. Examples include <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a> and gabapentinoids [<a href="#rid24">24-27</a>]. Potentiation of CNS effects of intravenous and inhalation anesthetic agents may also occur due to interactions with preoperative prescription drugs, supplements, recreational drugs, or alcohol  (<a class="graphic graphic_table graphicRef80618" href="/z/d/graphic/80618.html" rel="external">table 3</a>). Ingestion of such other agents in the preoperative period may be known or unknown to the anesthesiologist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of continuous infusions </strong>–<strong> </strong>If<strong> </strong>continuous infusions of sedative-hypnotic agents or opioids have been administered, considerations for termination of effect include the context-sensitive half-time of each agent (ie, the time required for plasma concentration to decline by 50 percent following discontinuation of a steady state infusion), as well as the duration of each agent's infusion. For <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> (the most commonly selected sedative-hypnotic agent), the low, flat plot of context-sensitive half-time correlates with a relatively short recovery time despite the duration of maintenance infusion  (<a class="graphic graphic_figure graphicRef118712" href="/z/d/graphic/118712.html" rel="external">figure 3</a>) (see  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Sedative-hypnotic agent: Propofol'</a>). For <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, a commonly selected opioid, the context-sensitive half-time after infusion is considerably longer (typically &gt;200 minutes after infusion at a maintenance dose for approximately three hours), while the context-sensitive half-time for the ultrashort-acting opioid <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> is only approximately four minutes, regardless of duration of administration  (<a class="graphic graphic_figure graphicRef109502" href="/z/d/graphic/109502.html" rel="external">figure 4</a>) (see  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'</a>). If other nonopioid adjuvant agents were also administered (eg, <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a>, <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, benzodiazepines), either as part of a TIVA technique or to decrease the MAC during an inhalation anesthetic technique or as an opioid-free anesthetic technique, their effects also influence recovery time. (See  <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Adjuvant agents'</a>.)</p><p></p><p class="headingAnchor" id="H212477494"><span class="h2">Assess and reverse effects of neuromuscular blocking agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess degree of muscle relaxation</strong> – If a nondepolarizing neuromuscular blocking agent (NMBA) was administered, the degree of residual neuromuscular blockade is determined using a peripheral nerve stimulator. Residual neuromuscular block is associated with weakness of upper airway muscles and increased risk of hypoventilation and hypoxemia, as well as risk for aspiration and postoperative pulmonary complications. Full recovery of neuromuscular function (ie, train-of-four [TOF] ratio of ≥0.9) must be achieved prior to extubation of the trachea. We avoid use of the peripheral nerve stimulator to induce a tetanic stimulus just before TOF stimulation, as this may lead to underestimation of the degree of residual neuromuscular blockade if the patient is extubated shortly after the augmented TOF assessment. (See  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Avoidance of residual neuromuscular blockade'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administer reversal agents</strong> – Appropriate doses of reversal agents (ie, <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">neostigmine</a> or <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">sugammadex</a>) are based on the level of existing neuromuscular block at the time of administration  (<a class="graphic graphic_table graphicRef114082" href="/z/d/graphic/114082.html" rel="external">table 4</a>). In some cases, reversal of neuromuscular blockade can occur by spontaneous recovery. (See  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Reversal of neuromuscular block'</a>.)</p><p></p><p class="headingAnchor" id="H1888212261"><span class="h2">Observe electroencephalographic evidence of return of consciousness</span><span class="headingEndMark"> — </span>Evaluation of raw electroencephalographic (EEG) waveform, if available, typically shows gradual loss of slow-delta and alpha oscillations, with return of higher-frequency beta and gamma oscillations as the patient regains consciousness [<a href="#rid28">28-30</a>]. However, the raw EEG waveform varies before full return of consciousness, depending on the anesthetic agents that were administered. Processed EEG may also be used to analyze raw EEG signal and monitor the depth of anesthesia. (See  <a class="medical medical_review" href="/z/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Brain monitoring'</a>.)</p><p class="headingAnchor" id="H1778605770"><span class="h2">Evaluate physiologic signs of return of consciousness</span><span class="headingEndMark"> — </span>During emergence, the patient's state of consciousness can be tracked by observing changes in physiologic signs  (<a class="graphic graphic_figure graphicRef113985" href="/z/d/graphic/113985.html" rel="external">figure 5</a>) [<a href="#rid30">30</a>]. Patients typically regain the ability to breathe spontaneously and shortly after the reversal of muscle relaxation and accumulation of carbon dioxide in the cerebral circulation. Although the respiratory pattern is typically irregular and tidal volumes are initially small, progression in the ability to breathe without assistance usually occurs within minutes [<a href="#rid30">30</a>]. Persistent hypoventilation and hypercapnia may be due to opioid effects and/or incomplete reversal of neuromuscular blocking agents. (See  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Opioids'</a> and  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Neuromuscular blocking agents'</a>.)</p><p>Swallowing and gagging reflexes, salivation, tearing, and grimacing typically occur concurrently with return of spontaneous breathing or shortly thereafter, indicating return of specific brainstem centers [<a href="#rid30">30</a>]. After reversal of a NMBA, return of the patient's muscle tone indicates return of function in motor circuits. Return of the corneal reflex indicates recovery of sensory function. Voluntary control of ocular movements indicates recovery of function in the midbrain, pons, and certain cortical cerebellar and basal ganglia circuits  (<a class="graphic graphic_figure graphicRef113985" href="/z/d/graphic/113985.html" rel="external">figure 5</a>) [<a href="#rid30">30</a>]. Finally, volitional demonstrations of volitional movements and responses to verbal commands indicate conscious awareness.</p><p>Notably, spontaneous eye opening is often one of the last signs observed during emergence from general anesthesia, and may occur well after reliable responses to verbal commands [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H4181515502"><span class="h2">Confirm antiemetic prophylaxis</span><span class="headingEndMark"> — </span>Specific agents and doses and timing for antiemetic prophylaxis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16849.html" rel="external">"Postoperative nausea and vomiting", section on 'Our strategy'</a>.)</p><p class="headingAnchor" id="H2656324483"><span class="h2">Evaluate adequacy of analgesia</span><span class="headingEndMark"> — </span>During return of consciousness, increases in HR, BP, and RR suggest that analgesia may be inadequate. Regional analgesic techniques or IV analgesic agents may be used to provide supplemental analgesia, as appropriate. Similar to the immediate postoperative setting, the timing, dose, and choice of agent or technique used to supplement analgesia during emergence should be tailored to the medical condition of the patient, likelihood of pain immediately after the specific surgical procedure, and whether the patient has a history of opioid dependency or abuse. (See  <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults"</a>.)</p><p>Pain relief during emergence may be accomplished by the administration of judicious doses of a longer-acting opioid such as <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>. Multimodal opioid-sparing strategies may also be utilized to achieve perioperative pain control. When possible, techniques such as surgical placement of a local surgical site infiltration, administration of an epidural analgesic dose, or performance of a transverse abdominis plane (TAP) block after abdominal surgery are employed shortly before emergence to decrease the required dose of IV opioids and other analgesic agents. (See  <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults", section on 'Creating a plan for analgesia'</a>.)</p><p class="headingAnchor" id="H968639175"><span class="h1">EMERGENCE WITH AN ENDOTRACHEAL TUBE</span><span class="headingEndMark"> — </span>In most cases, patients with an endotracheal tube are extubated at the end of the surgical or other intervention. This process may be associated with complications, including loss of the airway and the need to reintubate. Since extubation is an elective procedure, it should be planned in advance and executed when conditions are optimal [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/94224.html" rel="external">"Extubation following anesthesia", section on 'Extubation risk stratification'</a> and  <a class="medical medical_review" href="/z/d/html/94224.html" rel="external">"Extubation following anesthesia", section on 'Management of extubation'</a>.)</p><p>Techniques and pharmacologic agents to ameliorate physiologic responses to extubation (eg, sympathetic stimulation caused by stimulation of airway reflexes) are described separately. (See  <a class="medical medical_review" href="/z/d/html/94224.html" rel="external">"Extubation following anesthesia", section on 'Minimizing physiologic response to extubation'</a>.)</p><p class="headingAnchor" id="H4020716352"><span class="h2">Remifentanil extubation technique</span><span class="headingEndMark"> — </span>In selected cases, it is desirable to avoid all coughing or retching during extubation (eg, when there is patient risk with any increase in intracranial pressure or intraocular pressure). In such cases, an infusion of <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> (eg, approximately 0.1 mcg/kg per minute) may be briefly administered to allow tracheal extubation as soon as the patient can follow commands, which typically occurs before spontaneous respiratory efforts or recovery of airway reflexes. (See  <a class="medical medical_review" href="/z/d/html/96505.html" rel="external">"Anesthesia for emergency eye surgery", section on 'Emergence from anesthesia'</a> and  <a class="medical medical_review" href="/z/d/html/93391.html" rel="external">"Anesthesia for craniotomy in adults", section on 'Emergence from anesthesia'</a>.)</p><p class="headingAnchor" id="H194127540"><span class="h2">Postponed extubation</span><span class="headingEndMark"> — </span>In patients with respiratory failure, hemodynamic instability, airway edema, clinically-significant neuromuscular weakness, or known impaired sensorium, it is usually desirable to postpone extubation.</p><p class="headingAnchor" id="H1966162544"><span class="h3">Spontaneous ventilation</span><span class="headingEndMark"> — </span>In some cases, the patient may be breathing spontaneously, but the endotracheal tube (ETT) is left in place temporarily, with planned extubation in the post-anesthesia recovery unit (PACU) or intensive care unit (ICU). Spontaneous breathing without any ventilator support (eg, through a T-piece  (<a class="graphic graphic_figure graphicRef76022" href="/z/d/graphic/76022.html" rel="external">figure 6</a>)) may be allowed if the patient's work of breathing is not excessive. However, some patients may require a low level of pressure support using a ventilator (eg, inspiratory pressure augmentation of 5 to 8 cm H<sub>2</sub>O).</p><p>Transport of the patient from the operating room (OR) to another location is done cautiously if the patient is emerging from general anesthesia. Intratracheal movement of the in situ ETT may occur due to movement onto the bed or gurney in preparation for transport, and inadequate levels of anesthesia can cause bronchospasm, especially in patients with preexisting reactive airway disease. Intravenous (IV) medications administered to deepen anesthesia to avoid or treat bronchospasm may cause spontaneous breathing to cease, which necessitates initiation of ventilatory support.</p><p>When the patient successfully passes a number of pre-set physiologic criteria (eg, heart rate, respiratory rate, blood pressure, gas exchange) with no contraindications to extubation, the ETT can be removed. Patients should always be extubated at a location with all the necessary equipment (including airway devices) and personnel immediately available in case of loss of the airway after extubation. (See  <a class="medical medical_review" href="/z/d/html/1650.html" rel="external">"Initial weaning strategy in mechanically ventilated adults", section on 'Choosing a weaning method'</a> and  <a class="medical medical_review" href="/z/d/html/1650.html" rel="external">"Initial weaning strategy in mechanically ventilated adults"</a>.)</p><p class="headingAnchor" id="H570932191"><span class="h3">Controlled ventilation</span><span class="headingEndMark"> — </span>For patients requiring ongoing controlled ventilation, continued sedation/analgesia allows tolerance of the endotracheal tube. As surgery concludes, general anesthetic techniques used in the OR are converted to continuous sedation techniques (eg, <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> infusion with or without infusion of an opioid such as <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) in preparation for transfer of the intubated patient to the ICU. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a> and  <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects"</a>.)</p><p>Continuous sedation and controlled ventilation are maintained during transport of the intubated patient and during the subsequent handoff in the ICU. (See  <a class="medical medical_review" href="/z/d/html/94586.html" rel="external">"Handoffs of surgical patients"</a>.)</p><p class="headingAnchor" id="H1514808830"><span class="h1">EMERGENCE WITH A SUPRAGLOTTIC AIRWAY</span><span class="headingEndMark"> — </span>A supraglottic airway (SGA), such as a laryngeal mask airway, may be used as the planned airway management device (with either spontaneous or controlled ventilation). (See  <a class="medical medical_review" href="/z/d/html/98733.html" rel="external">"Supraglottic devices (including laryngeal mask airways) for airway management for anesthesia in adults"</a>.)</p><p>For patients who had ventilation by SGA during surgery, spontaneous breathing without assistance is resumed near the end of the procedure in preparation for SGA removal. Similar to requirements for endotracheal extubation, adequate reversal of neuromuscular blockade must be ensured prior to emergence from anesthesia (see <a class="local">'Assess and reverse effects of neuromuscular blocking agents'</a> above). To ensure airway patency after removal of the SGA, the patient must typically demonstrate return of airway reflexes and responses to verbal commands prior to removal. However, similar to "deep" extubation of an endotracheal tube (ETT), the SGA may be removed while the patient is still under general anesthesia after resumption of spontaneous breathing in selected patients who require avoidance of stimulation of airway reflexes and resultant coughing, straining, and hemodynamic stress.</p><p>After the removal of the SGA, oxygen (O<sub>2</sub>) is provided by face mask as the patient gradually emerges from anesthesia. Simple airway maneuvers may be necessary to maintain oxygenation and airway patency. Similar to emergence with an ETT, patients should always be extubated at a location with all the necessary equipment (including airway devices) and personnel immediately available in case of loss of the airway after extubation. (See  <a class="medical medical_review" href="/z/d/html/98733.html" rel="external">"Supraglottic devices (including laryngeal mask airways) for airway management for anesthesia in adults", section on 'Supraglottic airway-related complications'</a>.)</p><p class="headingAnchor" id="H3354137208"><span class="h1">EMERGENCE AFTER MASK VENTILATION</span><span class="headingEndMark"> — </span>Airway management with facemask alone is sometimes used for short cases when there is no surgical need for muscle relaxation, but only if the anesthesiologist will have full access to the patient's airway throughout the case. (See  <a class="medical medical_review" href="/z/d/html/91218.html" rel="external">"Airway management for induction of general anesthesia", section on 'Airway device options'</a> and  <a class="medical medical_review" href="/z/d/html/267.html" rel="external">"Basic airway management in adults", section on 'Bag-mask ventilation'</a>.)</p><p>For patients who were ventilated by facemask during surgery, spontaneous breathing without assistance is resumed at the end of the procedure. Techniques such as jaw thrust and oral or nasal airway insertion to avoid upper airway obstruction may be necessary in some patients, as well as continued administration of oxygen (O<sub>2</sub>) to avoid hypoxemia.</p><p class="headingAnchor" id="H546030418"><span class="h1">UNANTICIPATED NEED TO INTERRUPT THE EMERGENCE SEQUENCE</span><span class="headingEndMark"> — </span>In some cases, additional surgical interventions are determined to be necessary, or an unanticipated surgical complication occurs as the patient is emerging from general anesthesia. Such situations necessitate temporary re-establishment of a deeper level of anesthesia (ie, surgical or Stage III anesthesia  (<a class="graphic graphic_table graphicRef107796" href="/z/d/graphic/107796.html" rel="external">table 5</a>)).</p><p>Typically, this is accomplished by administration of an intravenous (IV) sedative-hypnotic agent such as <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>. A supplemental short-acting inhaled agent such as <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a> can be added if necessary.</p><p>If a surgical or other problem cannot be resolved after re-establishing general anesthesia, the patient may remain sedated and intubated with controlled ventilation. (See <a class="local">'Postponed extubation'</a> above.)</p><p class="headingAnchor" id="H355774398"><span class="h1">PROBLEMS DURING AND AFTER EMERGENCE</span><span class="headingEndMark"> — </span>Problems during or immediately after emergence that may require urgent treatment while the patient is still in the operating room (OR) include respiratory complications, hemodynamic instability, or severe emergence agitation. Transport from the OR to a post-anesthesia care unit (PACU) is delayed until the patient is able to maintain adequate oxygenation and ventilation during spontaneous ventilation, is hemodynamically stable, and can be aroused to follow verbal commands. (See  <a class="medical medical_review" href="/z/d/html/94586.html" rel="external">"Handoffs of surgical patients"</a>.)</p><p class="headingAnchor" id="H423237204"><span class="h2">Airway or respiratory problems</span><span class="headingEndMark"> — </span>Airway and respiratory problems requiring urgent treatment may occur during emergence from general anesthesia, typically before or immediately after removal of an artificial airway (eg, endotracheal tube [ETT] or supraglottic airway [SGA]):</p><p class="bulletIndent1"><span class="glyph">●</span>Prior to removal of an ETT or SGA, coughing and "bucking" on the artificial airway may be noted as the patient transitions through Stage II  (<a class="graphic graphic_table graphicRef107796" href="/z/d/graphic/107796.html" rel="external">table 5</a>), and this may be accompanied by bronchospasm. These reflex airway reactions to the noxious stimulus of the ETT or SGA may be attenuated by allowing spontaneous ventilation and/or administering small doses of intravenous (IV) <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> or an opioid. (See  <a class="medical medical_review" href="/z/d/html/94224.html" rel="external">"Extubation following anesthesia", section on 'Minimizing physiologic response to extubation'</a>.)</p><p></p><p class="bulletIndent1">In one randomized study, administration of <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> 1 mcg/kg at the end of the surgical procedure reduced the incidence of moderate to severe coughing (from 56 to 10 percent) compared with placebo [<a href="#rid32">32</a>]. However, 13 percent of patients receiving dexmedetomidine at this dose developed hypotension with systolic blood pressure (BP) &lt;90 mmHg, compared with none in the placebo group. (See <a class="local">'Hemodynamic instability'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Residual effects of neuromuscular blocking agents (NMBAs) may cause weakness with inadequate spontaneous ventilation and/or respiratory distress may occur before or after extubation. This is typically due to inadequate reversal of the effects of NMBAs. Inadequate muscle strength is confirmed with a peripheral nerve stimulator, and additional reversal agent is administered if indicated. Furthermore, persistent impairment of the peripheral chemoreflex with blunting of ventilatory responses to hypoxia can occur despite complete reversal of <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">rocuronium</a> with <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">neostigmine</a> or <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">sugammadex</a> [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Avoidance of residual neuromuscular blockade'</a> and  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Reversal of neuromuscular block'</a>.)</p><p></p><p class="bulletIndent1">Such residual weakness or reduced ventilatory responses to hypoxia may increase the risk for serious adverse respiratory events shortly after emergence from general anesthesia and in the PACU [<a href="#rid34">34,35</a>]. (See  <a class="medical medical_review" href="/z/d/html/94348.html" rel="external">"Respiratory problems in the post-anesthesia care unit (PACU)", section on 'Pharyngeal muscular weakness'</a> and  <a class="medical medical_review" href="/z/d/html/94348.html" rel="external">"Respiratory problems in the post-anesthesia care unit (PACU)", section on 'Neuromuscular blocking agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Apnea may occur before or after removal of an artificial airway. This is treated by resuming positive pressure ventilation via a mask while the patient is evaluated for residual effects of opioids or other anesthetic agents, residual neuromuscular blockade, hypothermia, or a neurologic disorder. (See  <a class="medical medical_review" href="/z/d/html/94348.html" rel="external">"Respiratory problems in the post-anesthesia care unit (PACU)", section on 'Central and peripheral nervous system abnormalities'</a>.)</p><p></p><p class="bulletIndent1">If indicated, additional reversal agent for a NMBA is administered. (See  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Reversal of neuromuscular block'</a> and  <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Avoidance of residual neuromuscular blockade'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> may be considered for reversal of opioid effects but is not routinely administered because of its potential adverse side effects (eg, acute severe pain, tachycardia, severe hypertension, flash pulmonary edema)  (<a class="graphic graphic_table graphicRef106215" href="/z/d/graphic/106215.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/94349.html" rel="external">"Cardiovascular problems in the post-anesthesia care unit (PACU)", section on 'Anesthetic agents'</a>.)</p><p></p><p class="bulletIndent1">In some cases, persistent apnea in the OR necessitates continued controlled ventilation while waiting for elimination of residual anesthetic agents or recovery of muscle strength. (See  <a class="medical medical_review" href="/z/d/html/94224.html" rel="external">"Extubation following anesthesia", section on 'Inability to tolerate extubation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laryngospasm may occur after removal of an ETT or SGA. This is treated by removing the noxious stimulus (eg, removal of blood or secretions by suctioning the airway) and employing positive pressure bag-mask ventilation concurrent with a jaw thrust maneuver. Also, applying pressure with fingertips to the "laryngospasm notch," which is the area between the mastoid process, the ramus of the mandible, and the base of the skull (also known as "Larson’s maneuver"  (<a class="graphic graphic_picture graphicRef122933" href="/z/d/graphic/122933.html" rel="external">picture 1</a>)), may rapidly reverse laryngospasm [<a href="#rid36">36-38</a>].</p><p></p><p class="bulletIndent1">If desaturation develops, it may be necessary to administer a small dose of IV <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> 0.1 mg/kg to relax the cords in order to achieve adequate ventilatory support and oxygenation. In some cases, emergency intubation or reintubation may be necessary. Thus, an anesthetic induction agent, full intubating dose of succinylcholine, assortment of ETTs, laryngoscope(s), and the anesthesia breathing circuit should remain immediately available while the patient is still in the OR.</p><p></p><p class="bulletIndent1">Possible scenarios in this setting include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If it is necessary to re-establish neuromuscular blockade to treat laryngospasm, <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> is typically selected. However, onset of muscle relaxation may be delayed due to presence of residual nondepolarizing NMBA, with occupation of a fraction of the post-junctional nicotinic receptors [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">rocuronium</a> is selected rather than <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>, a dose of 1.2 mg/kg if rocuronium is suggested within 30 minutes of <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">sugammadex</a> administration, and the minimum waiting time for muscle relaxation is five minutes [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If it is necessary to re-establish longer lasting neuromuscular blockade shortly after <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">sugammadex</a> has been administered, a nonsteroidal benzylisoquinolinium-based NMBA such as <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">cisatracurium</a> may be used (since sugammadex has no effect on neuromuscular blockade achieved with these agents) [<a href="#rid41">41,42</a>]. However, the onset of muscle relaxation may be delayed and the duration of blockade may be shortened [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Noncardiogenic negative pressure pulmonary edema may develop as a sequelae of airway obstruction due to biting that clamps off an ETT that is still in place, or due to laryngospasm or pharyngeal obstruction in a patient without an artificial airway. The mechanism is forceful inspiratory efforts against a closed glottis creating large negative intrathoracic pressures, increased left ventricular preload and afterload, and pulmonary capillary failure resulting in interstitial and alveolar edema and hemorrhage [<a href="#rid44">44</a>]. Onset is typically rapid, with severe respiratory distress and copious pink frothy secretions from the mouth or endotracheal tube.</p><p></p><p class="bulletIndent1">Treatment of noncardiogenic pulmonary edema is supportive. Supplemental oxygen (O<sub>2</sub>) is administered, and some patients receive diuretics. Endotracheal intubation or reintubation may be necessary if oxygenation is severely impaired, but a trial of noninvasive continuous positive airway pressure is appropriate if there are no contraindications. (See  <a class="medical medical_review" href="/z/d/html/94348.html" rel="external">"Respiratory problems in the post-anesthesia care unit (PACU)", section on 'Ventilatory support'</a> and  <a class="medical medical_review" href="/z/d/html/4401.html" rel="external">"Overview of the management of postoperative pulmonary complications", section on 'Pulmonary edema'</a>.)</p><p></p><p>In some patients, respiratory problems may develop or recur later after emergence, typically during transfer to the PACU or in the immediate postoperative period. (See  <a class="medical medical_review" href="/z/d/html/94348.html" rel="external">"Respiratory problems in the post-anesthesia care unit (PACU)"</a>.)</p><p class="headingAnchor" id="H1218166164"><span class="h2">Hemodynamic instability</span><span class="headingEndMark"> — </span>Emergence from general anesthesia is associated with increased sympathetic tone, hypertension, and tachycardia. Typically, this is due to discomfort due to the ETT or withdrawal of anesthetic and analgesic medications at the end of the surgical procedure, which may unmask pain. Increased sympathetic tone also occurs with agitation, coughing, or thrashing during emergence. Hypertension and tachycardia increase risk for cardiovascular complications in patients with cardiovascular disease (eg, coronary artery disease, congestive heart failure, chronic or poorly controlled hypertension), and increases in BP may cause bleeding complications at freshly sutured surgical sites. Although administration of <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> 1 mcg/kg at the end of the surgical procedure may reduce the incidence of hypertension and tachycardia compared with placebo, patients may develop hypotension (with systolic BP &lt;90 percent) [<a href="#rid32">32</a>]. A 2019 meta-analysis noted that hypotension and bradycardia frequently occurred after administration of dexmedetomidine, and sometimes persisted even after cessation of administration [<a href="#rid15">15</a>].</p><p>Pain is managed with IV administration of analgesic medications, such as an opioid or <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a>, or administration of a dose of a regional or neuraxial anesthetic medication. If pain is not the underlying cause of hypertension and/or tachycardia, administration of an IV dose of a beta blocker (eg, <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a>, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>) or other antihypertensive (eg, <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>) may be necessary. (See  <a class="medical medical_review" href="/z/d/html/94532.html" rel="external">"Hemodynamic management during anesthesia in adults", section on 'Hypertension: Prevention and treatment'</a> and  <a class="medical medical_review" href="/z/d/html/94357.html" rel="external">"Arrhythmias during anesthesia", section on 'Sinus tachycardia'</a>.)</p><p class="headingAnchor" id="H3519712307"><span class="h2">Delay or failure to emerge</span><span class="headingEndMark"> — </span>Causes and management delayed emergence are discussed in detail in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Delayed emergence'</a>.)</p><p class="headingAnchor" id="H1954977772"><span class="h2">Severe agitation</span><span class="headingEndMark"> — </span>Patients may become agitated during emergence as they transition through the delirium stage of general anesthesia (Stage II)  (<a class="graphic graphic_table graphicRef107796" href="/z/d/graphic/107796.html" rel="external">table 5</a>) [<a href="#rid45">45-48</a>]. Such transient agitation occurs in up to 19 percent of adult patients during emergence in the OR, depending on assessment criteria [<a href="#rid46">46,48</a>]. Some patients are extremely agitated with violent thrashing movements [<a href="#rid49">49</a>]. Although this stage is usually very brief (a few minutes), a struggling combative patient may jeopardize fresh surgical suture lines, orthopedic fixations, vascular grafts, drains, or intravascular catheters, or the patient may suffer a contusion, sprain, or corneal abrasion. Also, sympathetic stimulation in an agitated patient may result in severe tachycardia and hypertension. (See <a class="local">'Hemodynamic instability'</a> above.)</p><p>Often, noxious stimulation caused by the ETT is the primary cause of emergence agitation, with resolution immediately after the trachea is extubated. Patients who remain agitated after extubation should be further evaluated and treated before leaving the OR. Common causes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety and disinhibition caused by residual effects of anesthetics or adjuvant agents. (See  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Consider prolonged drug effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequately treated pain due to surgery or other discomfort (eg, urinary retention, trapped bowel gas, tight dressings). (See <a class="local">'Persistent pain'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Panic caused by dyspnea and respiratory distress. In particular, residual effects of NMBAs may cause muscle weakness with inadequate respiration and discoordinated flapping movements that may mimic agitation. (See <a class="local">'Airway or respiratory problems'</a> above and  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Neuromuscular blocking agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxemia or hypercarbia. (See  <a class="medical medical_review" href="/z/d/html/94348.html" rel="external">"Respiratory problems in the post-anesthesia care unit (PACU)"</a>.)</p><p></p><p>All possibilities are considered since multiple factors may be causative  (<a class="graphic graphic_table graphicRef106211" href="/z/d/graphic/106211.html" rel="external">table 7</a>). Although uncommon, a neurologic disorder, such as cerebral hypoperfusion or seizure activity, may manifest as agitation. (See  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Consider neurologic disorders'</a>.)</p><p>Management includes reassurance and reorientation while identifiable causes are being treated. Pharmacologic treatment of emergence agitation may be appropriate in selected patients before leaving the OR (eg, administration of small doses of opioid to treat pain, or a short-acting benzodiazepine or <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> to treat severe anxiety and agitation in a patient without pain) [<a href="#rid50">50</a>]. However, such analgesic, anxiolytic, or sedative agents should not be administered if hypoxemia, hypercapnia, hypoglycemia, or hypotension are a suspected cause of agitation.</p><p>In some cases, hyperactive delirium with agitation, hyperexcitability, disinhibition, crying, restlessness, and mental confusion may not become evident until later after emergence, or may persist or reappear during the early postoperative period after initial treatment. Management of this complication in the PACU setting is described separately. (See  <a class="medical medical_review" href="/z/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Emergence delirium'</a>.)</p><p class="headingAnchor" id="H2139988084"><span class="h2">Persistent pain</span><span class="headingEndMark"> — </span>Patients with evidence of pain immediately after emergence may require small doses of an opioid or other IV or regional analgesic agents to prepare for a smooth exit from the OR and transport to the PACU. Dosing of opioids must be judicious to avoid apnea during transport. Further management of acute pain in this setting is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults"</a>.)</p><p class="headingAnchor" id="H1950353859"><span class="h2">Persistent hypothermia</span><span class="headingEndMark"> — </span>Since even mild untreated postoperative hypothermia may cause complications, warming is continued uninterrupted at the end of the surgical procedure for patients with temperature &lt;36°C. A decrease in body temperature as little as 2°C slows metabolism of anesthetics and NMBAs. For this reason, if temperature is &lt;33°C, extubation is typically delayed until the patient can be adequately rewarmed. (See  <a class="medical medical_review" href="/z/d/html/94588.html" rel="external">"Perioperative temperature management", section on 'Prolongation of drug effects'</a>.)</p><p>After extubation at a temperature of &gt;35°C, active patient warming (eg, using a forced-air warming device) should be continued in the PACU until the temperature reaches 36°C. (See  <a class="medical medical_review" href="/z/d/html/94588.html" rel="external">"Perioperative temperature management", section on 'Postoperative temperature derangements'</a>.)</p><p class="headingAnchor" id="H591588380"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical emergence</strong> – Emergence is a passive process with the gradual return of consciousness after discontinuing administration of anesthetic and adjuvant agents at the end of the surgical procedure. Most patients transition smoothly from a surgical anesthetic state to an awake state with intact protective reflexes. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preparations for emergence</strong> – Preparations for emergence are initiated as the surgical procedure is ending. These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discontinuation of anesthetic agents and adjuvants. (See <a class="local">'Discontinue anesthetic agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assessment and reversal of effects of neuromuscular blocking agents (NMBAs). (See <a class="local">'Assess and reverse effects of neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of antiemetics. (See <a class="local">'Confirm antiemetic prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluation of adequacy of analgesia. (See <a class="local">'Evaluate adequacy of analgesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergence with an endotracheal tube</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In most cases, patients with an endotracheal tube (ETT) are extubated at the end of the surgical or other intervention when conditions are optimal. (See <a class="local">'Emergence with an endotracheal tube'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In selected cases when it is desirable to avoid all coughing or retching during extubation, an infusion of <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">remifentanil</a> (eg, approximately 0.1 mcg/kg per minute) may be briefly administered to allow tracheal extubation as soon as the patient can follow commands. (See <a class="local">'Remifentanil extubation technique'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with impaired sensorium, respiratory failure, airway edema, clinically significant neuromuscular weakness, or hemodynamic instability, it is usually desirable to postpone extubation. The ETT can remain in place, with either spontaneous ventilation or sedation with controlled ventilation. (See <a class="local">'Postponed extubation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergence with a supraglottic airway</strong> – A supraglottic airway (SGA), such as a laryngeal mask airway, is removed at the end of the surgical procedure after resumption of spontaneous breathing without assistance. Similar to requirements for endotracheal extubation, adequate reversal of NMBAs must be ensured. Other techniques to avoid airway complications during SGA removal are described above. (See <a class="local">'Emergence with a supraglottic airway'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergence after mask ventilation</strong> – In patients who had mask ventilation during surgery, spontaneous breathing without assistance is resumed at the end of the procedure, and techniques to avoid upper airway obstruction or hypoxemia are used if necessary. (See <a class="local">'Emergence after mask ventilation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interruption of emergence</strong> – In some cases, additional surgical interventions are deemed necessary, or an unanticipated surgical complication occurs as the patient is emerging from general anesthesia. Such situations necessitate temporary re-establishment of a deeper level of anesthesia  (<a class="graphic graphic_table graphicRef107796" href="/z/d/graphic/107796.html" rel="external">table 5</a>). (See <a class="local">'Unanticipated need to interrupt the emergence sequence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Problems during emergence</strong> – Problems during emergence may require urgent treatment (eg, airway or respiratory problems, hemodynamic instability, excessive somnolence, emergence agitation, persistent pain). Transport to the post-anesthesia care unit (PACU) is delayed until the patient can maintain adequate oxygenation and ventilation during spontaneous ventilation, is hemodynamically stable, can be aroused to follow verbal commands, is not agitated, and does not have moderate or severe pain. (See <a class="local">'Problems during and after emergence'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Khan KS, Hayes I, Buggy DJ. Pharmacology of anaesthetic agents II: inhalation anaesthetic agents. Continuing Education in Anaesthesia Critical Care &amp; Pain 2014; 14:106.</a></li><li><a class="nounderline abstract_t">Eger EI 2nd, Shafer SL. Tutorial: context-sensitive decrement times for inhaled anesthetics. Anesth Analg 2005; 101:688.</a></li><li><a class="nounderline abstract_t">Arain SR, Yu S, Dugan S, et al. Titration of sevoflurane anesthesia to optimize the time to regain airway reflexes in patients undergoing elective surgery: A randomized clinical trial comparing desflurane and sevoflurane anesthesia. Acta Anaesthesiol Scand 2020; 64:729.</a></li><li><a class="nounderline abstract_t">Peyton PJ, Chao I, Weinberg L, et al. Nitrous oxide diffusion and the second gas effect on emergence from anesthesia. Anesthesiology 2011; 114:596.</a></li><li><a class="nounderline abstract_t">Korman B, Dash RK, Peyton PJ. Can Mathematical Modeling Explain the Measured Magnitude of the Second Gas Effect? Anesthesiology 2018; 128:1075.</a></li><li><a class="nounderline abstract_t">van den Berg JP, Vereecke HE, Proost JH, et al. Pharmacokinetic and pharmacodynamic interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration. Br J Anaesth 2017; 118:44.</a></li><li><a class="nounderline abstract_t">Hendrickx JF, Eger EI 2nd, Sonner JM, Shafer SL. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. Anesth Analg 2008; 107:494.</a></li><li><a class="nounderline abstract_t">Torri G. Inhalation anesthetics: a review. Minerva Anestesiol 2010; 76:215.</a></li><li><a class="nounderline abstract_t">Piao G, Wu J. Systematic assessment of dexmedetomidine as an anesthetic agent: a meta-analysis of randomized controlled trials. Arch Med Sci 2014; 10:19.</a></li><li><a class="nounderline abstract_t">Gallego-Ligorit L, Vives M, Vallés-Torres J, et al. Use of Dexmedetomidine in Cardiothoracic and Vascular Anesthesia. J Cardiothorac Vasc Anesth 2018; 32:1426.</a></li><li><a class="nounderline abstract_t">Higuchi H, Adachi Y, Dahan A, et al. The interaction between propofol and clonidine for loss of consciousness. Anesth Analg 2002; 94:886.</a></li><li><a class="nounderline abstract_t">Dutta A, Sethi N, Sood J, et al. The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study. Anesth Analg 2019; 129:84.</a></li><li><a class="nounderline abstract_t">Dyck JB, Maze M, Haack C, et al. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology 1993; 78:821.</a></li><li><a class="nounderline abstract_t">Lodenius Å, Maddison KJ, Lawther BK, et al. Upper Airway Collapsibility during Dexmedetomidine and Propofol Sedation in Healthy Volunteers: A Nonblinded Randomized Crossover Study. Anesthesiology 2019; 131:962.</a></li><li><a class="nounderline abstract_t">Demiri M, Antunes T, Fletcher D, Martinez V. Perioperative adverse events attributed to α2-adrenoceptor agonists in patients not at risk of cardiovascular events: systematic review and meta-analysis. Br J Anaesth 2019; 123:795.</a></li><li><a class="nounderline abstract_t">Bowdle TA, Radant AD, Cowley DS, et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 1998; 88:82.</a></li><li><a class="nounderline abstract_t">Kleinloog D, Uit den Boogaard A, Dahan A, et al. Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers. J Psychopharmacol 2015; 29:401.</a></li><li><a class="nounderline abstract_t">Avidan MS, Maybrier HR, Abdallah AB, et al. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. Lancet 2017; 390:267.</a></li><li><a class="nounderline abstract_t">Weibel S, Jokinen J, Pace NL, et al. Efficacy and safety of intravenous lidocaine for postoperative analgesia and recovery after surgery: a systematic review with trial sequential analysis. Br J Anaesth 2016; 116:770.</a></li><li><a class="nounderline abstract_t">Altermatt FR, Bugedo DA, Delfino AE, et al. Evaluation of the effect of intravenous lidocaine on propofol requirements during total intravenous anaesthesia as measured by bispectral index. Br J Anaesth 2012; 108:979.</a></li><li><a class="nounderline abstract_t">Himes RS Jr, DiFazio CA, Burney RG. Effects of lidocaine on the anesthetic requirements for nitrous oxide and halothane. Anesthesiology 1977; 47:437.</a></li><li><a class="nounderline abstract_t">Rogers JF, Morrison AL, Nafziger AN, et al. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. Clin Pharmacol Ther 2002; 72:711.</a></li><li><a class="nounderline abstract_t">Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy 2004; 24:1177.</a></li><li><a class="nounderline abstract_t">Kizilcik N, Koner O. Magnesium Sulfate Reduced Opioid Consumption in Obese Patients Undergoing Sleeve Gastrectomy: a Prospective, Randomized Clinical Trial. Obes Surg 2018; 28:2783.</a></li><li><a class="nounderline abstract_t">Jabbour HJ, Naccache NM, Jawish RJ, et al. Ketamine and magnesium association reduces morphine consumption after scoliosis surgery: prospective randomised double-blind study. Acta Anaesthesiol Scand 2014; 58:572.</a></li><li><a class="nounderline abstract_t">Hah J, Mackey SC, Schmidt P, et al. Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial. JAMA Surg 2018; 153:303.</a></li><li><a class="nounderline abstract_t">Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain--a systematic review of randomized controlled trials. Pain 2006; 126:91.</a></li><li><a class="nounderline abstract_t">Brown EN, Lydic R, Schiff ND. General anesthesia, sleep, and coma. N Engl J Med 2010; 363:2638.</a></li><li><a class="nounderline abstract_t">Purdon PL, Sampson A, Pavone KJ, Brown EN. Clinical Electroencephalography for Anesthesiologists: Part I: Background and Basic Signatures. Anesthesiology 2015; 123:937.</a></li><li><a class="nounderline abstract_t">Reshef ER, Schiff ND, Brown EN. A Neurologic Examination for Anesthesiologists: Assessing Arousal Level during Induction, Maintenance, and Emergence. Anesthesiology 2019; 130:462.</a></li><li><a class="nounderline abstract_t">Wakabayashi K, le Roux JJ, Jooma Z. Reclaiming the Etiquette of Extubation. Anesth Analg 2023; 136:1220.</a></li><li><a class="nounderline abstract_t">Aouad MT, Zeeni C, Al Nawwar R, et al. Dexmedetomidine for Improved Quality of Emergence From General Anesthesia: A Dose-Finding Study. Anesth Analg 2019; 129:1504.</a></li><li><a class="nounderline abstract_t">Broens SJL, Boon M, Martini CH, et al. Reversal of Partial Neuromuscular Block and the Ventilatory Response to Hypoxia: A Randomized Controlled Trial in Healthy Volunteers. Anesthesiology 2019; 131:467.</a></li><li><a class="nounderline abstract_t">Stewart PA, Liang SS, Li QS, et al. The Impact of Residual Neuromuscular Blockade, Oversedation, and Hypothermia on Adverse Respiratory Events in a Postanesthetic Care Unit: A Prospective Study of Prevalence, Predictors, and Outcomes. Anesth Analg 2016; 123:859.</a></li><li><a class="nounderline abstract_t">Pandit JJ, Eriksson LI. Reversing Neuromuscular Blockade: Not Just the Diaphragm, but Carotid Body Function Too. Anesthesiology 2019; 131:453.</a></li><li><a class="nounderline abstract_t">Shinjo T, Inoue S, Egawa J, et al. Two cases in which the effectiveness of "laryngospasm notch" pressure against laryngospasm was confirmed by imaging examinations. J Anesth 2013; 27:761.</a></li><li><a class="nounderline abstract_t">Abelson D. Laryngospasm notch pressure ('Larson's maneuver') may have a role in laryngospasm management in children: highlighting a so far unproven technique. Paediatr Anaesth 2015; 25:1175.</a></li><li><a class="nounderline abstract_t">Larson CP Jr. Laryngospasm--the best treatment. Anesthesiology 1998; 89:1293.</a></li><li><a class="nounderline abstract_t">Cullen DJ. The effect of pretreatment with nondepolarizing muscle relaxants on the neuromuscular blocking action of succinylcholine. Anesthesiology 1971; 35:572.</a></li><li class="breakAll">Bridion (suggamadex) injection [package insert]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; 2015.</li><li><a class="nounderline abstract_t">Bom A, Hope F. Neuromuscular block induced by rocuronium and reversed by the encapsulating agent Org 25969 can be re-established using the non-steroidal neuromuscular blockers succinylcholine and cis-atracurium: A-457. Eur J Anaesthesiol 2005; 22.</a></li><li><a class="nounderline abstract_t">Kopman AF. Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology 2006; 104:631.</a></li><li><a class="nounderline abstract_t">Cammu G, de Kam PJ, De Graeve K, et al. Repeat dosing of rocuronium 1.2 mg kg-1 after reversal of neuromuscular block by sugammadex 4.0 mg kg-1 in anaesthetized healthy volunteers: a modelling-based pilot study. Br J Anaesth 2010; 105:487.</a></li><li><a class="nounderline abstract_t">Krodel DJ, Bittner EA, Abdulnour R, et al. Case scenario: acute postoperative negative pressure pulmonary edema. Anesthesiology 2010; 113:200.</a></li><li><a class="nounderline abstract_t">Hewer CL. THE STAGES AND SIGNS OF GENERAL ANAESTHESIA. Br Med J 1937; 2:274.</a></li><li><a class="nounderline abstract_t">Card E, Pandharipande P, Tomes C, et al. Emergence from general anaesthesia and evolution of delirium signs in the post-anaesthesia care unit. Br J Anaesth 2015; 115:411.</a></li><li><a class="nounderline abstract_t">Guenther U, Riedel L, Radtke FM. Patients prone for postoperative delirium: preoperative assessment, perioperative prophylaxis, postoperative treatment. Curr Opin Anaesthesiol 2016; 29:384.</a></li><li><a class="nounderline abstract_t">Munk L, Andersen G, Møller AM. Post-anaesthetic emergence delirium in adults: incidence, predictors and consequences. Acta Anaesthesiol Scand 2016; 60:1059.</a></li><li><a class="nounderline abstract_t">Carvalho DZ, Townley RA, Burkle CM, et al. Propofol Frenzy: Clinical Spectrum in 3 Patients. Mayo Clin Proc 2017; 92:1682.</a></li><li><a class="nounderline abstract_t">Viswanath O, Kerner B, Jean Y-K, et al. Emergence delirium: a narrative review. J Anesthesiol Clin Sci 2015; 4:2.</a></li></ol></div><div id="topicVersionRevision">Topic 94537 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pharmacology of anaesthetic agents II: inhalation anaesthetic agents</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16115976" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tutorial: context-sensitive decrement times for inhaled anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32057088" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Titration of sevoflurane anesthesia to optimize the time to regain airway reflexes in patients undergoing elective surgery: A randomized clinical trial comparing desflurane and sevoflurane anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21270630" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nitrous oxide diffusion and the second gas effect on emergence from anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29481374" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Can Mathematical Modeling Explain the Measured Magnitude of the Second Gas Effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28039241" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacokinetic and pharmacodynamic interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633028" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20203550" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Inhalation anesthetics: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24701209" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Systematic assessment of dexmedetomidine as an anesthetic agent: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29325842" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Use of Dexmedetomidine in Cardiothoracic and Vascular Anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11916791" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The interaction between propofol and clonidine for loss of consciousness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29787410" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098191" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31403974" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Upper Airway Collapsibility during Dexmedetomidine and Propofol Sedation in Healthy Volunteers: A Nonblinded Randomized Crossover Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31623842" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Perioperative adverse events attributed toα2-adrenoceptor agonists in patients not at risk of cardiovascular events: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9447860" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25693889" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28576285" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27199310" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy and safety of intravenous lidocaine for postoperative analgesia and recovery after surgery: a systematic review with trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22490315" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluation of the effect of intravenous lidocaine on propofol requirements during total intravenous anaesthesia as measured by bispectral index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/911052" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of lidocaine on the anesthetic requirements for nitrous oxide and halothane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12496752" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15460178" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Paradoxical reactions to benzodiazepines: literature review and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754384" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Magnesium Sulfate Reduced Opioid Consumption in Obese Patients Undergoing Sleeve Gastrectomy: a Prospective, Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635528" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ketamine and magnesium association reduces morphine consumption after scoliosis surgery: prospective randomised double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29238824" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16846695" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gabapentin and postoperative pain--a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190458" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : General anesthesia, sleep, and coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26275092" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical Electroencephalography for Anesthesiologists: Part I: Background and Basic Signatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30664547" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A Neurologic Examination for Anesthesiologists: Assessing Arousal Level during Induction, Maintenance, and Emergence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37205806" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reclaiming the Etiquette of Extubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31743169" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dexmedetomidine for Improved Quality of Emergence From General Anesthesia: A Dose-Finding Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31045894" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reversal of Partial Neuromuscular Block and the Ventilatory Response to Hypoxia: A Randomized Controlled Trial in Healthy Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27537929" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Impact of Residual Neuromuscular Blockade, Oversedation, and Hypothermia on Adverse Respiratory Events in a Postanesthetic Care Unit: A Prospective Study of Prevalence, Predictors, and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31206374" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Reversing Neuromuscular Blockade: Not Just the Diaphragm, but Carotid Body Function Too.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23494677" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Two cases in which the effectiveness of "laryngospasm notch" pressure against laryngospasm was confirmed by imaging examinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26426878" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Laryngospasm notch pressure ('Larson's maneuver') may have a role in laryngospasm management in children: highlighting a so far unproven technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9822036" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Laryngospasm--the best treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4256556" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The effect of pretreatment with nondepolarizing muscle relaxants on the neuromuscular blocking action of succinylcholine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4256556" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effect of pretreatment with nondepolarizing muscle relaxants on the neuromuscular blocking action of succinylcholine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Neuromuscular block induced by rocuronium and reversed by the encapsulating agent Org 25969 can be re-established using the non-steroidal neuromuscular blockers succinylcholine and cis-atracurium: A-457</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571954" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sugammadex: a revolutionary approach to neuromuscular antagonism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20630888" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Repeat dosing of rocuronium 1.2 mg kg-1 after reversal of neuromuscular block by sugammadex 4.0 mg kg-1 in anaesthetized healthy volunteers: a modelling-based pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20526178" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Case scenario: acute postoperative negative pressure pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20780832" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : THE STAGES AND SIGNS OF GENERAL ANAESTHESIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540068" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Emergence from general anaesthesia and evolution of delirium signs in the post-anaesthesia care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26905874" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Patients prone for postoperative delirium: preoperative assessment, perioperative prophylaxis, postoperative treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26968337" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Post-anaesthetic emergence delirium in adults: incidence, predictors and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29101936" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Propofol Frenzy: Clinical Spectrum in 3 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Emergence delirium: a narrative review</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
